Drug Trial Radar · NCT02645370
Efficacy and Safety of Danzhen
Last checked: Nov 19, 2026Latest source record: Jan 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,300
Planned (sponsor's estimate)
Start
Feb 2016
Primary completion
Jul 2017
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ecion Pharmaceutical CO..LTD
- First posted
- Jan 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose is to evaluate the effectiveness and safety profile of Danzhen for the prophylaxis of migraine in a "real-world" setting.
Conditions
- Migraine
Interventions
DanzhenDrug
TopiramateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- A 50% or greater reduction in headache days/month during the third treatment month of maintenance phase relative to baseline phase with one of the study drugs.Time frame: at baseline phase/the third treatment month of maintenance phase
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing Hospital
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.